Novartis SOSTOS
October 14, 2025
This study aims to investigate whether multiple sclerosis patients who haven’t had a relapse within the past year would benefit from switching to ofatumumab VS. continuing their current therapy, based on measures of disease activity, and a baseline neurofilament light level. Neurofilament is a marker of nerve cell loss in...